According to the associated press, gunshots rang out near the government building in Kiev, Ukraine.

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

AIFC Governor Renat Bekturov: Kazakhstan Is the Gateway for Chinese Capital Moving West

​Renat Bekturov, Governor of the Astana International Financial Centre (AIFC), recently led a delegation to China, hosting "AIFC CONNECT: SHANGHAI 2026" in Shanghai.

Politburo Meeting Sets Tone for "15th Five-Year Plan" Start, Addressing "Involuted" Competition and Implementing "AI Plus" Initiative

On April 28, the Political Bureau of the CPC Central Committee (中共中央政治局) held a meeting to analyze the current economic situation. The meeting noted that China's economy saw a strong start in the first quarter (GDP grew 5.0% year-on-year), with major indicators exceeding expectations. As the first Politburo meeting focused on economic work following the start of the "15th Five-Year Plan" (十五五) cycle, it released policy signals characterized by a high sense of urgency.

Chinese tech giant Huawei and Vietnam’s SHB Bank enter strategic partnership to accelerate penetration into SE Asia's financial cloud market

On April 22, Saigon-Hanoi Commercial Joint Stock Bank (SHB) of Vietnam officially announced the signing of a strategic cooperation agreement with Chinese tech giant Huawei. Under the agreement, Huawei will be deeply involved in SHB’s technical architecture design, assisting in the construction of its core data platform and providing comprehensive operational stability and security assurance.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.